CIK 0001446847
- Accelerated filer
- Smaller reporting company
IRONWOOD PHARMACEUTICALS INC
Sign in to watch- Ticker
- IRWD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043404176
- Phone
- +1 617-621-7722
- Business address
- 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-10 | Shetzline Michael SVP, CMO, Head-Res&Drug | Grant or award | +136,612 | 658,037 | ||
| 2026-02-24 | Shetzline Michael SVP, CMO, Head-Res&Drug | Sale | +17,012 | $3.66 | $62K | 521,425 |
| 2026-02-23 | Shetzline Michael SVP, CMO, Head-Res&Drug | Sale | −15,570 | $3.81 | $59K | 538,437 |
| 2025-02-10 | Shetzline Michael SVP, CMO, Head-Res&Drug | Grant or award | +133,333 | 595,276 | ||
| 2025-02-10 | Shetzline Michael SVP, CMO, Head-Res&Drug | Sale | −41,269 | $1.76 | $73K | 554,007 |
| 2025-01-17 | Shetzline Michael SVP, CMO, Head-Res&Drug | Grant or award | +48,224 | 461,943 | ||
| 2024-05-20 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −16,128 | $6.45 | $104K | 413,719 |
| 2024-03-08 | Shetzline Michael CMO,SVP,Head-Res&Drug | Option exercise | +34,936 | 429,847 | ||
| 2024-03-08 | Shetzline Michael CMO,SVP,Head-Res&Drug | Option exercise · Performance-based Restricted Stock Unit | −34,936 | 0 | ||
| 2024-02-12 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −38,618 | $15.24 | $589K | 340,484 |
| 2024-02-12 | Shetzline Michael CMO,SVP,Head-Res&Drug | Grant or award | +54,427 | 394,911 | ||
| 2024-02-12 | Shetzline Michael CMO,SVP,Head-Res&Drug | Grant or award · Performance-based Restricted Stock Unit | +27,214 | 27,214 | ||
| 2024-01-17 | Shetzline Michael CMO,SVP,Head-Res&Drug | Grant or award | +57,971 | 379,102 | ||
| 2023-05-22 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −10,324 | $10.12 | $104K | 321,131 |
| 2023-03-08 | Shetzline Michael CMO,SVP,Head-Res&Drug | Grant or award | +69,869 | 331,455 | ||
| 2023-03-08 | Shetzline Michael CMO,SVP,Head-Res&Drug | Grant or award · Performance-based Restricted Stock Units | +34,935 | 34,935 | ||
| 2023-02-28 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −7,438 | $11.31 | $84K | 264,002 |
| 2023-02-28 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −2,416 | $11.31 | $27K | 261,586 |
| 2023-02-27 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −7,146 | $11.41 | $82K | 273,762 |
| 2023-02-27 | Shetzline Michael CMO,SVP,Head-Res&Drug | Sale | −2,322 | $11.41 | $26K | 271,440 |
Page 1 of 2 · 31 trades